Pharmacological differentiation of the central 5-hydroxytryptamine-like actions of MK-212 (6-chloro-2[1-piperazinyl]-pyrazine),p-methoxyamphetamine and fenfluramine in an in vivo model system.
D000662:Amphetamines / Q000494:pharmacology*; D000818:Animals; D003913:Dextroamphetamine / Q000494:pharmacology; D004347:Drug Interactions; D010134:Fenclonine / Q000494:pharmacology; D005277:Fenfluramine / Q000494:pharmacology*; D005473:Fluoxetine / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D008711:Metergoline / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D011719:Pyrazines / Q000494:pharmacology*; D051381:Rats; D012701:Serotonin / Q000502:physiology*; D013997:Time Factors
D000662:Amphetamines; D010879:Piperazines; D011719:Pyrazines; D005473:Fluoxetine; D008711:Metergoline; D005277:Fenfluramine; D012701:Serotonin; C014896:6-chloro-2-(1-piperazinyl)pyrazine; D010134:Fenclonine; D003913:Dextroamphetamine